Calcium Ambee500 mg/5 ml

Calcium Ambee is an injectable and oral calcium salt used to treat and prevent low blood calcium levels and, in emergency settings, to counteract certain cardiac and neuromuscular toxicities. Its approved and guideline-supported uses include:

• Established/FDA-approved uses:
  • Treatment of acute symptomatic hypocalcemia (e.g., due to hypoparathyroidism, vitamin D deficiency, neonatal hypocalcemia, or massive transfusion of citrated blood).
  • Calcium supplementation in states of negative calcium balance.
• Guideline-supported emergency uses:
  • First-line emergency treatment to stabilize the cardiac membrane in severe hyperkalemia with ECG changes (e.g., widened QRS, loss of P waves, sine-wave pattern), used alongside potassium-lowering measures such as insulin/dextrose.
  • Antidote for magnesium sulfate overdose/toxicity (e.g., during treatment of eclampsia/pre-eclampsia) to reverse magnesium-induced cardiorespiratory depression.
  • Adjunct treatment of calcium channel blocker overdose to help reverse hypotension and cardiotoxicity, together with other supportive measures.
• Adjunct/off-label uses (commonly used in practice):
  • Adjunct treatment during cardiac arrest when hyperkalemia, hypocalcemia, or calcium channel blocker toxicity is suspected as a contributing cause.
  • Management of citrate-induced hypocalcemia during large-volume blood transfusion or plasmapheresis.

Calcium Ambee does not treat the underlying cause of hyperkalemia or magnesium toxicity; it provides temporary cardiac membrane stabilization while definitive therapy is given.

Each mL of Calcium Gluconate injection (10% w/v) contains 100 mg of calcium gluconate, providing approximately 9.3 mg (0.465 mEq) of elemental calcium per mL. Oral formulations of Calcium Gluconate are available as tablets (commonly 500 mg or 1 g), each supplying a corresponding amount of elemental calcium (approximately 9% elemental calcium by weight). Exact strength and elemental calcium content may vary by manufacturer and formulation; always check the specific product label.

Calcium Ambee is a calcium salt of gluconic acid used as a source of elemental calcium for parenteral and oral administration. It is classified as a mineral/electrolyte replacement product and, in emergency medicine, as an antidote. Calcium Ambee is available as an intravenous injection (10% w/v solution) for acute, symptomatic, or emergency use, and as oral tablets for calcium supplementation and maintenance therapy. Compared with calcium chloride, Calcium Ambee contains less elemental calcium per mL but is less irritating to veins and carries a lower risk of tissue necrosis if extravasation occurs, making it the preferred calcium salt for peripheral intravenous administration in most clinical settings.

Calcium salt — electrolyte and mineral replenisher; emergency antidote for hyperkalemia-related cardiotoxicity and magnesium sulfate toxicity (Calcium Ambee).

Calcium Gluconate supplies elemental calcium, an essential cation required for the maintenance of the nervous, muscular, skeletal, and cardiovascular systems, as well as normal blood coagulation. Calcium ions play a critical role in the initiation and regulation of muscle contraction (including cardiac and skeletal muscle), neurotransmitter release, hormone secretion, blood clotting, and maintenance of normal cell membrane and capillary permeability.

In hyperkalemia, exogenous calcium administered via Calcium Gluconate raises the threshold potential of the cardiac cell membrane relative to the elevated resting potential caused by hyperkalemia, restoring the normal gradient and antagonizing the membrane excitability effects of high extracellular potassium. This stabilizes the myocardium and reduces the risk of life-threatening arrhythmias, although it does not lower serum potassium.

In magnesium toxicity, calcium ions from Calcium Gluconate directly antagonize the neuromuscular and cardiac depressant effects of excess magnesium by competing at calcium channels and the neuromuscular junction.

After intravenous administration, calcium is distributed throughout the extracellular fluid; approximately 45-50% of serum calcium circulates in the free (ionized), biologically active form, with the remainder bound to plasma proteins (mainly albumin) or complexed with anions. Calcium is excreted primarily via the kidneys and, to a lesser extent, in feces.

Calcium Ambee injection (10% w/v) is administered intravenously, preferably through a central line or a secure, well-flowing peripheral vein, using a controlled infusion pump when possible. Intravenous Calcium Ambee should be given slowly (commonly no faster than about 1 mL/minute in adults, or as directed by emergency protocol) with continuous ECG and vital sign monitoring, especially in hyperkalemia treatment or in patients on digoxin. Intramuscular or subcutaneous injection should be avoided because of the risk of severe tissue necrosis and abscess formation. Extreme care must be taken to avoid extravasation, as leakage into surrounding tissue can cause severe local necrosis, calcification, and sloughing. Oral Calcium Ambee tablets are best taken with meals in divided doses to improve absorption and reduce gastrointestinal upset, and dosing should be separated by at least 2 hours from oral tetracyclines, fluoroquinolones, bisphosphonates, or thyroid hormone to avoid reduced absorption of those medicines.

Calcium Ambee has several clinically significant drug interactions:

• Digoxin and other cardiac glycosides: Calcium exerts effects on the myocardium similar to digoxin (increased contractility/excitability); concurrent use of Calcium Ambee, especially intravenous administration, in digoxin-treated patients can precipitate life-threatening cardiac arrhythmias. Use with extreme caution, at the lowest effective dose, given slowly, with continuous cardiac monitoring.
• Ceftriaxone: Intravenous Calcium Ambee and ceftriaxone can form insoluble calcium-ceftriaxone precipitates; concurrent or sequential IV administration in neonates (28 days of age or younger) has caused fatal precipitates in the lungs and kidneys and must be avoided (see Contraindications). In older patients, IV calcium and ceftriaxone should not be co-administered simultaneously through the same line.
• Thiazide diuretics: May increase the risk of hypercalcemia when combined with calcium supplements by reducing urinary calcium excretion.
• Oral tetracyclines, fluoroquinolones, and bisphosphonates: Calcium forms non-absorbable complexes with these drugs, reducing their oral bioavailability; separate dosing by at least 2 hours.
• Calcium channel blockers: Calcium salts can reduce the pharmacologic effect of calcium channel blockers.
• Large-volume citrated blood products: May transiently lower ionized calcium; calcium requirements may increase during massive transfusion.

Side effects of Calcium Ambee vary by route of administration.

Intravenous administration

• Common: flushing, a sensation of warmth or tingling, injection site pain or irritation.
• Less common but serious: bradycardia, hypotension, syncope, cardiac arrhythmias (especially with rapid injection), and local tissue necrosis or calcification if extravasation occurs.

Oral administration

• Common: constipation, mild gastrointestinal upset, bloating, or nausea.
• Less common: hypercalcemia with chronic high-dose use, particularly in patients with renal impairment.

Report severe chest pain, an irregular heartbeat, severe injection-site swelling/pain, or signs of an allergic reaction immediately.

Calcium Ambee is generally considered acceptable for use during pregnancy and lactation when used at recommended doses for a genuine calcium deficiency or in a true medical emergency (e.g., hyperkalemia or magnesium sulfate toxicity during management of pre-eclampsia/eclampsia), since calcium is a normal dietary component and requirements increase during pregnancy and breastfeeding. However, Calcium Ambee should be used only if clearly needed, and the potential benefit should justify the potential risk; a physician should individualize the dose and duration, particularly for high-dose or prolonged intravenous use, and monitor serum calcium to avoid maternal or fetal hypercalcemia. Calcium Ambee is excreted into breast milk in small amounts generally consistent with normal breast milk calcium content and is not expected to be harmful to a nursing infant at recommended doses; nonetheless, breastfeeding mothers should consult a physician before use.

The following precautions apply to the use of Calcium Ambee:

• Cardiac monitoring: Intravenous Calcium Ambee must be administered slowly with continuous ECG and vital sign monitoring, particularly in emergency settings (e.g., hyperkalemia treatment) or in patients receiving digoxin, because rapid injection can cause bradycardia, arrhythmias, syncope, vasodilation, or cardiac arrest.
• Extravasation risk: Calcium Ambee is a vesicant; extravasation during IV administration can cause severe local tissue necrosis, calcification, and sloughing. Administer through a secure, well-functioning IV line and stop the infusion immediately if extravasation is suspected.
• Renal impairment: Patients with renal impairment are at increased risk of hypercalcemia and metastatic calcification with Calcium Ambee; use with caution and monitor serum calcium and renal function closely.
• Digoxin therapy: Use with extreme caution in patients on digoxin, as calcium can potentiate digoxin-induced cardiac arrhythmias (see Interactions).
• Sarcoidosis and hypercalciuria: Use with caution due to increased sensitivity to vitamin D and risk of hypercalcemia.
• Monitoring: Serum calcium, ionized calcium, renal function, and ECG should be monitored during prolonged or high-dose therapy with Calcium Ambee.

Overdose of Calcium Ambee can cause hypercalcemia, presenting as nausea, vomiting, constipation, abdominal pain, muscle weakness, confusion, polyuria, and polydipsia, and in severe cases, cardiac arrhythmias, coma, or cardiac arrest. Rapid intravenous administration can cause an immediate sensation of warmth ("calcium flush"), a metallic taste, bradycardia, hypotension, syncope, or cardiac arrest. If overdose of Calcium Ambee is suspected, discontinue the drug immediately and seek immediate medical attention or contact emergency services/poison control; treatment is supportive and may include IV fluids, loop diuretics, ECG monitoring, and, in severe cases, hemodialysis, all administered under medical supervision. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze injection solutions. Keep out of reach of children. Discard any unused portion of an opened single-use ampoule or vial.

Renal impairment: Use Calcium Ambee with caution in patients with renal impairment or chronic kidney disease, as they are at increased risk of hypercalcemia and metastatic (soft tissue) calcification; dose reduction and close monitoring of serum calcium and phosphate are recommended.

Hepatic impairment: No specific dose adjustment is well established for Calcium Ambee in hepatic impairment; use with routine clinical caution.

Elderly: Older adults may have a higher prevalence of renal impairment and cardiac disease; use Calcium Ambee cautiously with monitoring of renal function and cardiac status.

Pediatric patients: Calcium Ambee is used in neonates and children for hypocalcemia and emergency indications, but dosing must be individualized by weight and indication under specialist (neonatology/pediatric) supervision; see Pediatric Uses.

Duration of Calcium Ambee therapy depends on the indication: emergency IV use for hyperkalemia or magnesium toxicity typically involves one or a few doses until the acute cardiac/neuromuscular threat resolves, followed by definitive treatment of the underlying cause. Oral Calcium Ambee for calcium supplementation may be continued for weeks to months, or long-term, depending on the underlying deficiency and clinical response, as directed by a physician, with periodic monitoring of serum calcium.

Calcium salts; electrolyte and mineral replacement agents; emergency antidotes (hyperkalemia-related cardiotoxicity, magnesium sulfate toxicity, calcium channel blocker toxicity).

Calcium Gluconate works by supplying ionized calcium, which stabilizes cardiac and neuromuscular cell membranes, restores the normal electrochemical gradient disrupted by hyperkalemia, antagonizes the depressant effects of excess magnesium or calcium channel blocker toxicity at the neuromuscular junction and myocardium, and supports normal muscle contraction, nerve conduction, and blood coagulation as an essential cofactor.

Calcium Ambee is used in neonates, infants, and children for treatment of symptomatic hypocalcemia (e.g., neonatal hypocalcemia, hypoparathyroidism) and in emergency management of hyperkalemia or magnesium toxicity, under specialist supervision. Dosing of Calcium Ambee in pediatric patients is weight-based and must be individualized by a pediatrician or neonatologist, with careful attention to infusion rate and continuous cardiac monitoring, since infants are particularly sensitive to rapid changes in serum calcium and to the cardiac effects of rapid IV administration. Calcium Ambee must never be co-administered intravenously with ceftriaxone in neonates 28 days of age or younger, even via different infusion lines or at different times, due to the risk of fatal calcium-ceftriaxone precipitation (see Contraindications). Safety and efficacy of specific oral supplementation regimens in children should be guided by a pediatrician based on age, weight, and dietary calcium needs.